0.799
-0.01 (-1.50%)
| Penutupan Terdahulu | 0.811 |
| Buka | 0.820 |
| Jumlah Dagangan | 700,273 |
| Purata Dagangan (3B) | 1,653,723 |
| Modal Pasaran | 67,493,104 |
| Harga / Jualan (P/S) | 0.990 |
| Harga / Buku (P/B) | 2.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Operasi (TTM) | -272.84% |
| EPS Cair (TTM) | -2.92 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 51.91% |
| Nisbah Semasa (MRQ) | 2.16 |
| Aliran Tunai Operasi (OCF TTM) | -194.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.28 M |
| Pulangan Atas Aset (ROA TTM) | -39.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -679.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Sutro Biopharma, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.88 |
|
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.58% |
| % Dimiliki oleh Institusi | 70.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Mar 2025 | 7,462,495 |
| Merck & Co., Inc. | 31 Mar 2025 | 2,723,509 |
| Eversept Partners, Lp | 31 Mar 2025 | 2,292,261 |
| Samsara Biocapital, Llc | 31 Mar 2025 | 2,196,814 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 2.00 (HC Wainwright & Co., 150.28%) | Pegang |
| Median | 1.40 (75.20%) | |
| Rendah | 0.800 (B of A Securities, 0.11%) | Jual |
| Purata | 1.40 (75.20%) | |
| Jumlah | 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 0.875 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 19 May 2025 | 0.800 (0.11%) | Jual | 0.880 |
| HC Wainwright & Co. | 29 Apr 2025 | 2.00 (150.28%) | Pegang | 0.870 |
| 17 Mar 2025 | 2.00 (150.28%) | Pegang | 0.930 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Jun 2025 | Pengumuman | Sutro Biopharma Appoints Greg Chow as Chief Financial Officer |
| 08 May 2025 | Pengumuman | Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights |
| 01 May 2025 | Pengumuman | Sutro Biopharma to Participate in Upcoming Investor Conferences |
| 28 Apr 2025 | Pengumuman | Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |